Schlumberger Announces Expiration of Tender Offer for Any and All of Schlumberger Investment SA’s Outstanding 3.300% Senior Notes Due 2021
Schlumberger Limited (“Schlumberger”) today announced the expiration of the previously announced cash tender offer by Schlumberger Investment SA, an indirect wholly-owned subsidiary of Schlumberger (“SISA”), for any and all of SISA’s outstanding 3.300% Senior Notes due 2021 (the “Notes”), on the terms and subject to the conditions set forth in the Offer to Purchase dated June 17, 2020 (the “Offer to Purchase”) and the related Notice of Guaranteed Delivery attached to the Offer to Purchase (the “Notice of Guaranteed Delivery”). The tender offer is referred to as the “Offer.” The Offer to Purchase and the Notice of Guaranteed Delivery are referred to together as the “Offer Documents.” The Offer expired at 5:00 p.m., New York City time, today, June 23, 2020 (the “Expiration Time”). As of the Expiration Time, valid tenders had been received (and not withdrawn) in the amounts set forth in the table below.
Title of Security
3.300% Senior Notes due 2021
(1) Excludes Notes tendered through the guaranteed delivery procedures set forth in the Offer to Purchase.
SISA expects to accept for purchase all Notes validly tendered and not validly withdrawn in the Offer, including Notes tendered in accordance with the guaranteed delivery procedures set forth in the Offer to Purchase. Payment for the Notes purchased pursuant to the Offer is intended to be made on June 26, 2020 (the “Settlement Date”).
The applicable “Tender Offer Consideration” will be $1,026.06 for each $1,000 principal amount of Notes, plus accrued and unpaid interest to, but not including, the Settlement Date, payable on the Settlement Date.
The Offer was made pursuant to the Offer to Purchase and the Notice of Guaranteed Delivery. D.F. King & Co., Inc. acted as the tender agent and information agent for the Offer. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC acted as dealer managers and Standard Chartered Bank and UniCredit Capital Markets LLC acted as co-dealer managers for the Offer.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “believe,” “plan,” “estimate,” “intend,” “anticipate,” “should,” “could,” “will,” “see,” “likely,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements regarding the terms and timing for completion of the Offer, including the acceptance for purchase of any Notes validly tendered and the expected Settlement Date thereof. Schlumberger and SISA cannot give any assurance that such statements will prove correct. These statements are subject to, among other things, the risks and uncertainties detailed in Schlumberger’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission. Actual outcomes may vary materially from those reflected in Schlumberger’s forward-looking statements. The forward-looking statements speak only as of the date of this press release, and both Schlumberger and SISA disclaim any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
Simon Farrant – Vice President of Investor Relations, Schlumberger Limited
Joy V. Domingo – Director of Investor Relations, Schlumberger Limited
Office +1 (713) 375-3535
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome2.7.2020 10:00:00 CEST | Press release
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said:“Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – wi
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries2.7.2020 09:34:00 CEST | Press release
Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience. Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient
Telstra Wholesale deploys ADVA technology in Australian-first Ethernet service2.7.2020 09:00:00 CEST | Press release
ADVA (FSE: ADV) today announced that Telstra Wholesale has deployed its FSP 150 packet edge device with LTE backup to deliver the new Ethernet Access – Mobile Backup service. Unique to the Australian market, the offering improves service availability and strengthens business continuity. With Layer 2 mobile backup capabilities, ADVA’s technology automatically switches traffic to Telstra Wholesale’s 4G mobile network if fiber connectivity fails. This helps to provide peace of mind for enterprise customers that no longer have the burden of configuring costly mobile backup and recovery systems. The new service is the latest stage in a long-standing partnership between ADVA and Telstra Wholesale, which has been key to advancing the reliability and resiliency of Ethernet services for Telstra Wholesale customers throughout Australia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005024/en/ ADVA’s packet edge technology is he
Urethral Stricture Treatment by Hybrid Cell Therapy, Granted Japanese Patent2.7.2020 08:00:00 CEST | Press release
Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to patients who had recurrence of the disease after earlier conventional treatments, has been reported by this method called “Bees-Haus” (Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture; https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701006026/en/ Biomaterial research facility of JBM in Tokyo, where improvised scaffolds for regenerative medicine applications like Bees-haus, implants and medical devices are developed. (Photo: Business Wire) Male urethra, a tubular passage to let the urine out from urinary bladder, when affected with narrowing or stricture of the lumen, causes difficulty in voiding urine, urinary retention, and pain
Two in Five Fortune 500 Companies Choose Alibaba Cloud2.7.2020 08:00:00 CEST | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, said today it has supported 38 percent of the Fortune 500 companies over the past fiscal year. With this milestone, the cloud service provider plans to accelerate its globalization strategy, aiming to become the world’s leading digital intelligence backbone in three years. “We are extremely confident in the future of the global digital economy, especially with the digitalization of healthcare, business, education, leisure and other parts of our lives during the pandemic. As the largest cloud service provider in the Asia Pacific region, we will continue increasing investments in the next three years to strengthen our infrastructure, our solutions and our role in the wider technology ecosystem towards being the trusted partner of choice not just in Asia Pacific, but for the global digital economy by 2023,” said Jeff Zhang, president of Alibaba Cloud Intelligence, at the Alibaba Cloud Summit 2020 event. Cons
Alibaba Cloud and Unilever to Usher in Next-Generation Digital Marketing Initiatives2.7.2020 08:00:00 CEST | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, is partnering with Unilever, one of the biggest multinational consumer goods companies, in a pioneering strategic initiative that will enable Unilever to action on next-generation digital marketing campaigns. In the partnership, Unilever will be able to utilize Alibaba Cloud’s trusted artificial intelligence (AI) and cloud-based technologies to optimize its omni-channel, online and offline demand generation activities. With intelligent analysis, Alibaba Cloud’s solutions can help to unlock detailed insights into Unilever’s customers buying patterns and behavior. The data-driven business intelligence could help Unilever accelerate the creation of new and precisely targeted digital marketing campaigns. It could also enable Unilever to predict more precisely and quickly respond to changing customer buying habits across multiple platforms. Taking Unilever’s digital marketing to the next level, Alibaba Cloud’s